Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     GLP-1 analogue
33 records.
Article ID PMID Source Title Publish Year
A01770 34622555 Diabetes Obes Metab Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. 2021 Details
A01961 34552561 Front Endocrinol (Lausanne) GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. 2021 Details
A04163 33732030 Clin Pharmacol Clinical Impact of Liraglutide as a Treatment of Obesity. 2021 Details
A05535 33216087 Food Funct Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. 2020 Details
A06026 33036179 J Clin Med One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. 2020 Details
A06274 32945071 Diabetes Obes Metab A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? 2020 Details
A06902 32704556 Endocrinol Diabetes Metab Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. 2020 Details
A07726 32375182 Horm Metab Res Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells. 2020 Details
A07888 32322207 Front Pharmacol Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. 2020 Details
A08267 32180556 Mol Metab Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. 2020 Details
A10676 31241045 Gen Physiol Biophys Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. 2019 Details
A12156 30578967 Biochim Biophys Acta Mol Cell Biol Lipids Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. 2018 Details
A12514 30413050 Pharmaceuticals (Basel) Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? 2018 Details
A12630 30359962 Pharmacol Res Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2018 Details
A15850 28681988 Diabetes Obes Metab Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. 2017 Details
A15862 28677333 Aliment Pharmacol Ther Review article: new treatments in non-alcoholic fatty liver disease. 2017 Details
A18326 27208776 Biochem Biophys Res Commun GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. 2016 Details
A18792 26937139 World J Gastroenterol Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. 2016 Details
A19360 26608256 Lancet Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. 2015 Details
A19727 26394161 J Hepatol Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. 2015 Details
A20234 26072069 J Huazhong Univ Sci Technolog Med Sci Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. 2015 Details
A20393 25994073 Diabetologia Incretin-based therapies: where will we be 50 years from now? 2015 Details
A21914 24966606 World J Gastroenterol Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. 2014 Details
A22871 24264040 Int J Mol Sci Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. 2013 Details
A22882 24256515 Clin Endocrinol (Oxf) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. 2013 Details
A22906 24222092 Semin Liver Dis The role of gastrointestinal hormones in hepatic lipid metabolism. 2013 Details
A23842 23432843 Liver Int GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. 2013 Details
A23956 23352496 J Diabetes Complications Potential of incretin-based therapies for non-alcoholic fatty liver disease. 2013 Details
A25528 21745271 Liver Int Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. 2011 Details
A34187 24189085 BMJ Open Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. 2013 Details
A49336 35784568 Front Endocrinol (Lausanne) Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children - From Disease Pathogenesis to Complications. 2022 Details
A49488 35739957 Antioxidants (Basel) Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. 2022 Details
A52370 28086952 J Med Case Rep Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. 2017 Details